文献速递白血病造血干细胞移植与细胞治疗

急性髓系白血病中诱导、巩固与维持治疗之间的界限日益模糊

The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia.
PubMed 文献 · Br J Haematol · 2022-12-26

该综述回顾了自20世纪70年代以来急性髓系白血病(AML)治疗的演变,从仅用蒽环类药物和阿糖胞苷追求血液学缓解,到通过支持治疗、异基因造血干细胞移植、遗传学分层和微小残留病检测使部分年轻成人获得长期生存。作者认为传统上将治疗划分为诱导、巩固和维持阶段的范式需要重新思考,并讨论了不断演变的新概念与范式。

要点

  • AML治疗从仅用蒽环类药物和阿糖胞苷追求血液学缓解,演变为部分年轻成人可获得长期生存。
  • 支持治疗(血小板输注、抗菌及抗真菌治疗)、现有药物更好使用和异基因造血干细胞移植推动了疗效进步。
  • 对移植免疫作用、疾病遗传学特征、微小残留病检测及新药的认识使治疗转向针对更可能应答患者的精细化策略。

核心结论

  • 历史上将AML视为通用诊断并适用于所有患者的范式,以及将治疗传统划分为诱导、巩固和维持阶段的做法,需要重新思考。

研究设计与样本

  • 综述类文章,回顾自20世纪70年代初以来AML治疗的演变,讨论不断演变的新概念与范式。

主要发现

  • 最初治疗仅基于蒽环类药物和阿糖胞苷两种药物,目标是获得血液学缓解使患者恢复并回家,治愈并非现实期望。
  • 此后数十年取得缓慢但显著进展,使一部分年轻成人成为长期生存者,这一成就最初并未使用新药。
  • 支持治疗发挥重要作用,包括血小板输注的广泛可及和抗菌治疗(尤其是抗真菌治疗)的改善。
  • 现有药物的更好使用和异基因造血干细胞移植的发展同样重要。
  • 最初关注最大耐受治疗,后因对异基因移植免疫作用的理解、疾病生物学更好的遗传学特征描述、微小残留病检测的先进工具以及近期新药研发,焦点转向针对更可能应答患者的更精细方法。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since the early 1970s, the treatment of acute myeloid leukaemia (AML) has undergone a major transformation. Initially based on only two drugs, an anthracycline and cytosine arabinoside, the aim of therapy was to achieve a haematological response allowing patients to recover and go home. Back in those early days, cure was not a realistic expectation. Treatment was analogous to a heart attack; upon recovery and a short respite, recurrence and death inevitably followed. Over the subsequent decades, slow but remarkable progress was made such that a subgroup of young adults could become long-term survivors. This astonishing feat was achieved initially without the use of new drugs. Supportive care played a major role with the widespread availability of platelet transfusions and improved antimicrobial therapy, particularly antifungal. No less important was the better use of existing drugs and the development of allogeneic haematopoietic cell transplantation. While initially the focus was on maximal tolerated therapy, an understanding of the immunologic role of allogeneic transplantation, better genetic characterization of the biology of the disease, advanced tools for detection of minimal disease as well as the recent development of new drugs changed the focus to a more refined approach targeting patients who are more likely to respond. Clearly, the historical paradigm where the term AML was generic and applicable to all patients requires a rethinking from the traditional therapeutic demarcations of therapy into phases of induction, consolidation and maintenance. These evolving new concepts and paradigm will be herein considered.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Frisch A, Rowe JM, Ofran Y, et al. The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia. Br J Haematol. 2022. PMID: 36572392. doi:10.1111/bjh.18613

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。